document_id int64 34 624 | file_name stringclasses 423
values | text stringclasses 423
values | document_type stringclasses 3
values | url stringclasses 421
values | spans stringclasses 423
values | hypothesis_id stringclasses 17
values | hypothesis stringclasses 17
values | short_description stringclasses 17
values | label stringclasses 3
values | evidence_spans stringlengths 2 159 |
|---|---|---|---|---|---|---|---|---|---|---|
619 | 1574111_0001193125-14-440569_d826999dex99d5.htm | EXHIBIT (d)(5)
MUTUAL NON-DISCLOSURE AGREEMENT
This Mutual Non-Disclosure Agreement (the “Agreement”), effective July 31, 2014 (the “Effective Date”), is by and between BioMarin Pharmaceutical Inc., a Delaware corporation, with offices at 105 Digital Drive, Novato, CA 94949 (“BioMarin”), and Prosensa Holding N.V., a Ne... | sec-html | https://www.sec.gov/Archives/edgar/data/0001574111/000119312514440569/d826999dex99d5.htm | [[0, 8], [8, 14], [15, 46], [47, 423], [423, 524], [524, 525], [526, 714], [714, 909], [910, 1020], [1021, 1033], [1033, 1628], [1628, 1792], [1793, 1822], [1822, 2139], [2139, 2210], [2211, 3086], [3087, 3408], [3409, 3583], [3584, 3766], [3767, 3776], [3776, 3881], [3881, 4179], [4180, 4221], [4222, 4243], [4243, 433... | nda-7 | Receiving Party may share some Confidential Information with some third-parties (including consultants, agents and professional advisors). | Sharing with third-parties | Entailment | [26] |
619 | 1574111_0001193125-14-440569_d826999dex99d5.htm | EXHIBIT (d)(5)
MUTUAL NON-DISCLOSURE AGREEMENT
This Mutual Non-Disclosure Agreement (the “Agreement”), effective July 31, 2014 (the “Effective Date”), is by and between BioMarin Pharmaceutical Inc., a Delaware corporation, with offices at 105 Digital Drive, Novato, CA 94949 (“BioMarin”), and Prosensa Holding N.V., a Ne... | sec-html | https://www.sec.gov/Archives/edgar/data/0001574111/000119312514440569/d826999dex99d5.htm | [[0, 8], [8, 14], [15, 46], [47, 423], [423, 524], [524, 525], [526, 714], [714, 909], [910, 1020], [1021, 1033], [1033, 1628], [1628, 1792], [1793, 1822], [1822, 2139], [2139, 2210], [2211, 3086], [3087, 3408], [3409, 3583], [3584, 3766], [3767, 3776], [3776, 3881], [3881, 4179], [4180, 4221], [4222, 4243], [4243, 433... | nda-17 | Receiving Party may create a copy of some Confidential Information in some circumstances. | Permissible copy | NotMentioned | [] |
619 | 1574111_0001193125-14-440569_d826999dex99d5.htm | EXHIBIT (d)(5)
MUTUAL NON-DISCLOSURE AGREEMENT
This Mutual Non-Disclosure Agreement (the “Agreement”), effective July 31, 2014 (the “Effective Date”), is by and between BioMarin Pharmaceutical Inc., a Delaware corporation, with offices at 105 Digital Drive, Novato, CA 94949 (“BioMarin”), and Prosensa Holding N.V., a Ne... | sec-html | https://www.sec.gov/Archives/edgar/data/0001574111/000119312514440569/d826999dex99d5.htm | [[0, 8], [8, 14], [15, 46], [47, 423], [423, 524], [524, 525], [526, 714], [714, 909], [910, 1020], [1021, 1033], [1033, 1628], [1628, 1792], [1793, 1822], [1822, 2139], [2139, 2210], [2211, 3086], [3087, 3408], [3409, 3583], [3584, 3766], [3767, 3776], [3776, 3881], [3881, 4179], [4180, 4221], [4222, 4243], [4243, 433... | nda-8 | Receiving Party shall notify Disclosing Party in case Receiving Party is required by law, regulation or judicial process to disclose any Confidential Information. | Notice on compelled disclosure | Entailment | [38] |
619 | 1574111_0001193125-14-440569_d826999dex99d5.htm | EXHIBIT (d)(5)
MUTUAL NON-DISCLOSURE AGREEMENT
This Mutual Non-Disclosure Agreement (the “Agreement”), effective July 31, 2014 (the “Effective Date”), is by and between BioMarin Pharmaceutical Inc., a Delaware corporation, with offices at 105 Digital Drive, Novato, CA 94949 (“BioMarin”), and Prosensa Holding N.V., a Ne... | sec-html | https://www.sec.gov/Archives/edgar/data/0001574111/000119312514440569/d826999dex99d5.htm | [[0, 8], [8, 14], [15, 46], [47, 423], [423, 524], [524, 525], [526, 714], [714, 909], [910, 1020], [1021, 1033], [1033, 1628], [1628, 1792], [1793, 1822], [1822, 2139], [2139, 2210], [2211, 3086], [3087, 3408], [3409, 3583], [3584, 3766], [3767, 3776], [3776, 3881], [3881, 4179], [4180, 4221], [4222, 4243], [4243, 433... | nda-13 | Receiving Party may acquire information similar to Confidential Information from a third party. | Permissible acquirement of similar information | Entailment | [31, 35] |
619 | 1574111_0001193125-14-440569_d826999dex99d5.htm | EXHIBIT (d)(5)
MUTUAL NON-DISCLOSURE AGREEMENT
This Mutual Non-Disclosure Agreement (the “Agreement”), effective July 31, 2014 (the “Effective Date”), is by and between BioMarin Pharmaceutical Inc., a Delaware corporation, with offices at 105 Digital Drive, Novato, CA 94949 (“BioMarin”), and Prosensa Holding N.V., a Ne... | sec-html | https://www.sec.gov/Archives/edgar/data/0001574111/000119312514440569/d826999dex99d5.htm | [[0, 8], [8, 14], [15, 46], [47, 423], [423, 524], [524, 525], [526, 714], [714, 909], [910, 1020], [1021, 1033], [1033, 1628], [1628, 1792], [1793, 1822], [1822, 2139], [2139, 2210], [2211, 3086], [3087, 3408], [3409, 3583], [3584, 3766], [3767, 3776], [3776, 3881], [3881, 4179], [4180, 4221], [4222, 4243], [4243, 433... | nda-5 | Receiving Party may share some Confidential Information with some of Receiving Party's employees. | Sharing with employees | Entailment | [26] |
619 | 1574111_0001193125-14-440569_d826999dex99d5.htm | EXHIBIT (d)(5)
MUTUAL NON-DISCLOSURE AGREEMENT
This Mutual Non-Disclosure Agreement (the “Agreement”), effective July 31, 2014 (the “Effective Date”), is by and between BioMarin Pharmaceutical Inc., a Delaware corporation, with offices at 105 Digital Drive, Novato, CA 94949 (“BioMarin”), and Prosensa Holding N.V., a Ne... | sec-html | https://www.sec.gov/Archives/edgar/data/0001574111/000119312514440569/d826999dex99d5.htm | [[0, 8], [8, 14], [15, 46], [47, 423], [423, 524], [524, 525], [526, 714], [714, 909], [910, 1020], [1021, 1033], [1033, 1628], [1628, 1792], [1793, 1822], [1822, 2139], [2139, 2210], [2211, 3086], [3087, 3408], [3409, 3583], [3584, 3766], [3767, 3776], [3776, 3881], [3881, 4179], [4180, 4221], [4222, 4243], [4243, 433... | nda-4 | Receiving Party shall not use any Confidential Information for any purpose other than the purposes stated in Agreement. | Limited use | Entailment | [24, 25] |
620 | 1592288_0001193125-17-306543_d469659dex99e2.htm | Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible negotiated business transaction involving Dimension Therapeutics, Inc. (the “Company”) and yo... | sec-html | https://www.sec.gov/Archives/edgar/data/0001592288/000119312517306543/d469659dex99e2.htm | [[0, 8], [8, 14], [15, 33], [34, 64], [65, 82], [83, 107], [108, 152], [153, 174], [175, 533], [533, 1188], [1188, 1572], [1572, 1637], [1637, 1955], [1955, 2106], [2106, 2289], [2289, 2461], [2461, 2750], [2751, 2801], [2801, 3055], [3055, 3174], [3175, 3231], [3231, 3327], [3327, 3382], [3382, 3413], [3413, 3491], [3... | nda-11 | Receiving Party shall not reverse engineer any objects which embody Disclosing Party's Confidential Information. | No reverse engineering | NotMentioned | [] |
620 | 1592288_0001193125-17-306543_d469659dex99e2.htm | Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible negotiated business transaction involving Dimension Therapeutics, Inc. (the “Company”) and yo... | sec-html | https://www.sec.gov/Archives/edgar/data/0001592288/000119312517306543/d469659dex99e2.htm | [[0, 8], [8, 14], [15, 33], [34, 64], [65, 82], [83, 107], [108, 152], [153, 174], [175, 533], [533, 1188], [1188, 1572], [1572, 1637], [1637, 1955], [1955, 2106], [2106, 2289], [2289, 2461], [2461, 2750], [2751, 2801], [2801, 3055], [3055, 3174], [3175, 3231], [3231, 3327], [3327, 3382], [3382, 3413], [3413, 3491], [3... | nda-16 | Receiving Party shall destroy or return some Confidential Information upon the termination of Agreement. | Return of confidential information | NotMentioned | [] |
620 | 1592288_0001193125-17-306543_d469659dex99e2.htm | Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible negotiated business transaction involving Dimension Therapeutics, Inc. (the “Company”) and yo... | sec-html | https://www.sec.gov/Archives/edgar/data/0001592288/000119312517306543/d469659dex99e2.htm | [[0, 8], [8, 14], [15, 33], [34, 64], [65, 82], [83, 107], [108, 152], [153, 174], [175, 533], [533, 1188], [1188, 1572], [1572, 1637], [1637, 1955], [1955, 2106], [2106, 2289], [2289, 2461], [2461, 2750], [2751, 2801], [2801, 3055], [3055, 3174], [3175, 3231], [3231, 3327], [3327, 3382], [3382, 3413], [3413, 3491], [3... | nda-15 | Agreement shall not grant Receiving Party any right to Confidential Information. | No licensing | NotMentioned | [] |
620 | 1592288_0001193125-17-306543_d469659dex99e2.htm | Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible negotiated business transaction involving Dimension Therapeutics, Inc. (the “Company”) and yo... | sec-html | https://www.sec.gov/Archives/edgar/data/0001592288/000119312517306543/d469659dex99e2.htm | [[0, 8], [8, 14], [15, 33], [34, 64], [65, 82], [83, 107], [108, 152], [153, 174], [175, 533], [533, 1188], [1188, 1572], [1572, 1637], [1637, 1955], [1955, 2106], [2106, 2289], [2289, 2461], [2461, 2750], [2751, 2801], [2801, 3055], [3055, 3174], [3175, 3231], [3231, 3327], [3327, 3382], [3382, 3413], [3413, 3491], [3... | nda-10 | Receiving Party shall not disclose the fact that Agreement was agreed or negotiated. | Confidentiality of Agreement | Entailment | [31, 32, 33] |
620 | 1592288_0001193125-17-306543_d469659dex99e2.htm | Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible negotiated business transaction involving Dimension Therapeutics, Inc. (the “Company”) and yo... | sec-html | https://www.sec.gov/Archives/edgar/data/0001592288/000119312517306543/d469659dex99e2.htm | [[0, 8], [8, 14], [15, 33], [34, 64], [65, 82], [83, 107], [108, 152], [153, 174], [175, 533], [533, 1188], [1188, 1572], [1572, 1637], [1637, 1955], [1955, 2106], [2106, 2289], [2289, 2461], [2461, 2750], [2751, 2801], [2801, 3055], [3055, 3174], [3175, 3231], [3231, 3327], [3327, 3382], [3382, 3413], [3413, 3491], [3... | nda-2 | Confidential Information shall only include technical information. | None-inclusion of non-technical information | NotMentioned | [] |
620 | 1592288_0001193125-17-306543_d469659dex99e2.htm | Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible negotiated business transaction involving Dimension Therapeutics, Inc. (the “Company”) and yo... | sec-html | https://www.sec.gov/Archives/edgar/data/0001592288/000119312517306543/d469659dex99e2.htm | [[0, 8], [8, 14], [15, 33], [34, 64], [65, 82], [83, 107], [108, 152], [153, 174], [175, 533], [533, 1188], [1188, 1572], [1572, 1637], [1637, 1955], [1955, 2106], [2106, 2289], [2289, 2461], [2461, 2750], [2751, 2801], [2801, 3055], [3055, 3174], [3175, 3231], [3231, 3327], [3327, 3382], [3382, 3413], [3413, 3491], [3... | nda-1 | All Confidential Information shall be expressly identified by the Disclosing Party. | Explicit identification | NotMentioned | [] |
620 | 1592288_0001193125-17-306543_d469659dex99e2.htm | Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible negotiated business transaction involving Dimension Therapeutics, Inc. (the “Company”) and yo... | sec-html | https://www.sec.gov/Archives/edgar/data/0001592288/000119312517306543/d469659dex99e2.htm | [[0, 8], [8, 14], [15, 33], [34, 64], [65, 82], [83, 107], [108, 152], [153, 174], [175, 533], [533, 1188], [1188, 1572], [1572, 1637], [1637, 1955], [1955, 2106], [2106, 2289], [2289, 2461], [2461, 2750], [2751, 2801], [2801, 3055], [3055, 3174], [3175, 3231], [3231, 3327], [3327, 3382], [3382, 3413], [3413, 3491], [3... | nda-19 | Some obligations of Agreement may survive termination of Agreement. | Survival of obligations | Entailment | [87, 88] |
620 | 1592288_0001193125-17-306543_d469659dex99e2.htm | Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible negotiated business transaction involving Dimension Therapeutics, Inc. (the “Company”) and yo... | sec-html | https://www.sec.gov/Archives/edgar/data/0001592288/000119312517306543/d469659dex99e2.htm | [[0, 8], [8, 14], [15, 33], [34, 64], [65, 82], [83, 107], [108, 152], [153, 174], [175, 533], [533, 1188], [1188, 1572], [1572, 1637], [1637, 1955], [1955, 2106], [2106, 2289], [2289, 2461], [2461, 2750], [2751, 2801], [2801, 3055], [3055, 3174], [3175, 3231], [3231, 3327], [3327, 3382], [3382, 3413], [3413, 3491], [3... | nda-12 | Receiving Party may independently develop information similar to Confidential Information. | Permissible development of similar information | Entailment | [11, 15] |
620 | 1592288_0001193125-17-306543_d469659dex99e2.htm | Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible negotiated business transaction involving Dimension Therapeutics, Inc. (the “Company”) and yo... | sec-html | https://www.sec.gov/Archives/edgar/data/0001592288/000119312517306543/d469659dex99e2.htm | [[0, 8], [8, 14], [15, 33], [34, 64], [65, 82], [83, 107], [108, 152], [153, 174], [175, 533], [533, 1188], [1188, 1572], [1572, 1637], [1637, 1955], [1955, 2106], [2106, 2289], [2289, 2461], [2461, 2750], [2751, 2801], [2801, 3055], [3055, 3174], [3175, 3231], [3231, 3327], [3327, 3382], [3382, 3413], [3413, 3491], [3... | nda-20 | Receiving Party may retain some Confidential Information even after the return or destruction of Confidential Information. | Permissible post-agreement possession | Entailment | [87, 88] |
620 | 1592288_0001193125-17-306543_d469659dex99e2.htm | Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible negotiated business transaction involving Dimension Therapeutics, Inc. (the “Company”) and yo... | sec-html | https://www.sec.gov/Archives/edgar/data/0001592288/000119312517306543/d469659dex99e2.htm | [[0, 8], [8, 14], [15, 33], [34, 64], [65, 82], [83, 107], [108, 152], [153, 174], [175, 533], [533, 1188], [1188, 1572], [1572, 1637], [1637, 1955], [1955, 2106], [2106, 2289], [2289, 2461], [2461, 2750], [2751, 2801], [2801, 3055], [3055, 3174], [3175, 3231], [3231, 3327], [3327, 3382], [3382, 3413], [3413, 3491], [3... | nda-3 | Confidential Information may include verbally conveyed information. | Inclusion of verbally conveyed information | Entailment | [9] |
620 | 1592288_0001193125-17-306543_d469659dex99e2.htm | Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible negotiated business transaction involving Dimension Therapeutics, Inc. (the “Company”) and yo... | sec-html | https://www.sec.gov/Archives/edgar/data/0001592288/000119312517306543/d469659dex99e2.htm | [[0, 8], [8, 14], [15, 33], [34, 64], [65, 82], [83, 107], [108, 152], [153, 174], [175, 533], [533, 1188], [1188, 1572], [1572, 1637], [1637, 1955], [1955, 2106], [2106, 2289], [2289, 2461], [2461, 2750], [2751, 2801], [2801, 3055], [3055, 3174], [3175, 3231], [3231, 3327], [3327, 3382], [3382, 3413], [3413, 3491], [3... | nda-18 | Receiving Party shall not solicit some of Disclosing Party's representatives. | No solicitation | Entailment | [48, 49, 50] |
620 | 1592288_0001193125-17-306543_d469659dex99e2.htm | Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible negotiated business transaction involving Dimension Therapeutics, Inc. (the “Company”) and yo... | sec-html | https://www.sec.gov/Archives/edgar/data/0001592288/000119312517306543/d469659dex99e2.htm | [[0, 8], [8, 14], [15, 33], [34, 64], [65, 82], [83, 107], [108, 152], [153, 174], [175, 533], [533, 1188], [1188, 1572], [1572, 1637], [1637, 1955], [1955, 2106], [2106, 2289], [2289, 2461], [2461, 2750], [2751, 2801], [2801, 3055], [3055, 3174], [3175, 3231], [3231, 3327], [3327, 3382], [3382, 3413], [3413, 3491], [3... | nda-7 | Receiving Party may share some Confidential Information with some third-parties (including consultants, agents and professional advisors). | Sharing with third-parties | Entailment | [16, 18, 19, 20, 31, 32] |
620 | 1592288_0001193125-17-306543_d469659dex99e2.htm | Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible negotiated business transaction involving Dimension Therapeutics, Inc. (the “Company”) and yo... | sec-html | https://www.sec.gov/Archives/edgar/data/0001592288/000119312517306543/d469659dex99e2.htm | [[0, 8], [8, 14], [15, 33], [34, 64], [65, 82], [83, 107], [108, 152], [153, 174], [175, 533], [533, 1188], [1188, 1572], [1572, 1637], [1637, 1955], [1955, 2106], [2106, 2289], [2289, 2461], [2461, 2750], [2751, 2801], [2801, 3055], [3055, 3174], [3175, 3231], [3231, 3327], [3327, 3382], [3382, 3413], [3413, 3491], [3... | nda-17 | Receiving Party may create a copy of some Confidential Information in some circumstances. | Permissible copy | NotMentioned | [] |
620 | 1592288_0001193125-17-306543_d469659dex99e2.htm | Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible negotiated business transaction involving Dimension Therapeutics, Inc. (the “Company”) and yo... | sec-html | https://www.sec.gov/Archives/edgar/data/0001592288/000119312517306543/d469659dex99e2.htm | [[0, 8], [8, 14], [15, 33], [34, 64], [65, 82], [83, 107], [108, 152], [153, 174], [175, 533], [533, 1188], [1188, 1572], [1572, 1637], [1637, 1955], [1955, 2106], [2106, 2289], [2289, 2461], [2461, 2750], [2751, 2801], [2801, 3055], [3055, 3174], [3175, 3231], [3231, 3327], [3327, 3382], [3382, 3413], [3413, 3491], [3... | nda-8 | Receiving Party shall notify Disclosing Party in case Receiving Party is required by law, regulation or judicial process to disclose any Confidential Information. | Notice on compelled disclosure | Entailment | [35, 36] |
620 | 1592288_0001193125-17-306543_d469659dex99e2.htm | Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible negotiated business transaction involving Dimension Therapeutics, Inc. (the “Company”) and yo... | sec-html | https://www.sec.gov/Archives/edgar/data/0001592288/000119312517306543/d469659dex99e2.htm | [[0, 8], [8, 14], [15, 33], [34, 64], [65, 82], [83, 107], [108, 152], [153, 174], [175, 533], [533, 1188], [1188, 1572], [1572, 1637], [1637, 1955], [1955, 2106], [2106, 2289], [2289, 2461], [2461, 2750], [2751, 2801], [2801, 3055], [3055, 3174], [3175, 3231], [3231, 3327], [3327, 3382], [3382, 3413], [3413, 3491], [3... | nda-13 | Receiving Party may acquire information similar to Confidential Information from a third party. | Permissible acquirement of similar information | Entailment | [11, 12] |
620 | 1592288_0001193125-17-306543_d469659dex99e2.htm | Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible negotiated business transaction involving Dimension Therapeutics, Inc. (the “Company”) and yo... | sec-html | https://www.sec.gov/Archives/edgar/data/0001592288/000119312517306543/d469659dex99e2.htm | [[0, 8], [8, 14], [15, 33], [34, 64], [65, 82], [83, 107], [108, 152], [153, 174], [175, 533], [533, 1188], [1188, 1572], [1572, 1637], [1637, 1955], [1955, 2106], [2106, 2289], [2289, 2461], [2461, 2750], [2751, 2801], [2801, 3055], [3055, 3174], [3175, 3231], [3231, 3327], [3327, 3382], [3382, 3413], [3413, 3491], [3... | nda-5 | Receiving Party may share some Confidential Information with some of Receiving Party's employees. | Sharing with employees | Entailment | [16, 18, 19, 20, 31, 32] |
620 | 1592288_0001193125-17-306543_d469659dex99e2.htm | Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible negotiated business transaction involving Dimension Therapeutics, Inc. (the “Company”) and yo... | sec-html | https://www.sec.gov/Archives/edgar/data/0001592288/000119312517306543/d469659dex99e2.htm | [[0, 8], [8, 14], [15, 33], [34, 64], [65, 82], [83, 107], [108, 152], [153, 174], [175, 533], [533, 1188], [1188, 1572], [1572, 1637], [1637, 1955], [1955, 2106], [2106, 2289], [2289, 2461], [2461, 2750], [2751, 2801], [2801, 3055], [3055, 3174], [3175, 3231], [3231, 3327], [3327, 3382], [3382, 3413], [3413, 3491], [3... | nda-4 | Receiving Party shall not use any Confidential Information for any purpose other than the purposes stated in Agreement. | Limited use | Entailment | [18] |
621 | 1609351_0001193125-19-066373_d642137dex99d2.htm | Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeutics, Inc., a Delaware corporation, having an address at 3737 Market Street, Suite 1300... | sec-html | https://www.sec.gov/Archives/edgar/data/0001609351/000119312519066373/d642137dex99d2.htm | [[0, 11], [11, 17], [18, 49], [50, 468], [468, 1066], [1067, 1079], [1079, 1683], [1684, 1713], [1713, 2054], [2054, 2113], [2113, 2149], [2149, 2200], [2200, 2238], [2238, 2251], [2251, 2274], [2274, 3093], [3094, 3110], [3110, 3139], [3139, 3259], [3259, 3346], [3346, 3754], [3754, 3967], [3967, 4129], [4129, 4386], ... | nda-11 | Receiving Party shall not reverse engineer any objects which embody Disclosing Party's Confidential Information. | No reverse engineering | NotMentioned | [] |
621 | 1609351_0001193125-19-066373_d642137dex99d2.htm | Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeutics, Inc., a Delaware corporation, having an address at 3737 Market Street, Suite 1300... | sec-html | https://www.sec.gov/Archives/edgar/data/0001609351/000119312519066373/d642137dex99d2.htm | [[0, 11], [11, 17], [18, 49], [50, 468], [468, 1066], [1067, 1079], [1079, 1683], [1684, 1713], [1713, 2054], [2054, 2113], [2113, 2149], [2149, 2200], [2200, 2238], [2238, 2251], [2251, 2274], [2274, 3093], [3094, 3110], [3110, 3139], [3139, 3259], [3259, 3346], [3346, 3754], [3754, 3967], [3967, 4129], [4129, 4386], ... | nda-16 | Receiving Party shall destroy or return some Confidential Information upon the termination of Agreement. | Return of confidential information | Entailment | [46] |
621 | 1609351_0001193125-19-066373_d642137dex99d2.htm | Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeutics, Inc., a Delaware corporation, having an address at 3737 Market Street, Suite 1300... | sec-html | https://www.sec.gov/Archives/edgar/data/0001609351/000119312519066373/d642137dex99d2.htm | [[0, 11], [11, 17], [18, 49], [50, 468], [468, 1066], [1067, 1079], [1079, 1683], [1684, 1713], [1713, 2054], [2054, 2113], [2113, 2149], [2149, 2200], [2200, 2238], [2238, 2251], [2251, 2274], [2274, 3093], [3094, 3110], [3110, 3139], [3139, 3259], [3259, 3346], [3346, 3754], [3754, 3967], [3967, 4129], [4129, 4386], ... | nda-15 | Agreement shall not grant Receiving Party any right to Confidential Information. | No licensing | Entailment | [45, 49] |
621 | 1609351_0001193125-19-066373_d642137dex99d2.htm | Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeutics, Inc., a Delaware corporation, having an address at 3737 Market Street, Suite 1300... | sec-html | https://www.sec.gov/Archives/edgar/data/0001609351/000119312519066373/d642137dex99d2.htm | [[0, 11], [11, 17], [18, 49], [50, 468], [468, 1066], [1067, 1079], [1079, 1683], [1684, 1713], [1713, 2054], [2054, 2113], [2113, 2149], [2149, 2200], [2200, 2238], [2238, 2251], [2251, 2274], [2274, 3093], [3094, 3110], [3110, 3139], [3139, 3259], [3259, 3346], [3346, 3754], [3754, 3967], [3967, 4129], [4129, 4386], ... | nda-10 | Receiving Party shall not disclose the fact that Agreement was agreed or negotiated. | Confidentiality of Agreement | Entailment | [33, 34, 35] |
621 | 1609351_0001193125-19-066373_d642137dex99d2.htm | Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeutics, Inc., a Delaware corporation, having an address at 3737 Market Street, Suite 1300... | sec-html | https://www.sec.gov/Archives/edgar/data/0001609351/000119312519066373/d642137dex99d2.htm | [[0, 11], [11, 17], [18, 49], [50, 468], [468, 1066], [1067, 1079], [1079, 1683], [1684, 1713], [1713, 2054], [2054, 2113], [2113, 2149], [2149, 2200], [2200, 2238], [2238, 2251], [2251, 2274], [2274, 3093], [3094, 3110], [3110, 3139], [3139, 3259], [3259, 3346], [3346, 3754], [3754, 3967], [3967, 4129], [4129, 4386], ... | nda-2 | Confidential Information shall only include technical information. | None-inclusion of non-technical information | Contradiction | [8, 9, 10, 11, 12, 13, 14, 15] |
621 | 1609351_0001193125-19-066373_d642137dex99d2.htm | Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeutics, Inc., a Delaware corporation, having an address at 3737 Market Street, Suite 1300... | sec-html | https://www.sec.gov/Archives/edgar/data/0001609351/000119312519066373/d642137dex99d2.htm | [[0, 11], [11, 17], [18, 49], [50, 468], [468, 1066], [1067, 1079], [1079, 1683], [1684, 1713], [1713, 2054], [2054, 2113], [2113, 2149], [2149, 2200], [2200, 2238], [2238, 2251], [2251, 2274], [2274, 3093], [3094, 3110], [3110, 3139], [3139, 3259], [3259, 3346], [3346, 3754], [3754, 3967], [3967, 4129], [4129, 4386], ... | nda-1 | All Confidential Information shall be expressly identified by the Disclosing Party. | Explicit identification | Entailment | [45] |
621 | 1609351_0001193125-19-066373_d642137dex99d2.htm | Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeutics, Inc., a Delaware corporation, having an address at 3737 Market Street, Suite 1300... | sec-html | https://www.sec.gov/Archives/edgar/data/0001609351/000119312519066373/d642137dex99d2.htm | [[0, 11], [11, 17], [18, 49], [50, 468], [468, 1066], [1067, 1079], [1079, 1683], [1684, 1713], [1713, 2054], [2054, 2113], [2113, 2149], [2149, 2200], [2200, 2238], [2238, 2251], [2251, 2274], [2274, 3093], [3094, 3110], [3110, 3139], [3139, 3259], [3259, 3346], [3346, 3754], [3754, 3967], [3967, 4129], [4129, 4386], ... | nda-19 | Some obligations of Agreement may survive termination of Agreement. | Survival of obligations | Entailment | [82] |
621 | 1609351_0001193125-19-066373_d642137dex99d2.htm | Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeutics, Inc., a Delaware corporation, having an address at 3737 Market Street, Suite 1300... | sec-html | https://www.sec.gov/Archives/edgar/data/0001609351/000119312519066373/d642137dex99d2.htm | [[0, 11], [11, 17], [18, 49], [50, 468], [468, 1066], [1067, 1079], [1079, 1683], [1684, 1713], [1713, 2054], [2054, 2113], [2113, 2149], [2149, 2200], [2200, 2238], [2238, 2251], [2251, 2274], [2274, 3093], [3094, 3110], [3110, 3139], [3139, 3259], [3259, 3346], [3346, 3754], [3754, 3967], [3967, 4129], [4129, 4386], ... | nda-12 | Receiving Party may independently develop information similar to Confidential Information. | Permissible development of similar information | Entailment | [25, 29] |
621 | 1609351_0001193125-19-066373_d642137dex99d2.htm | Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeutics, Inc., a Delaware corporation, having an address at 3737 Market Street, Suite 1300... | sec-html | https://www.sec.gov/Archives/edgar/data/0001609351/000119312519066373/d642137dex99d2.htm | [[0, 11], [11, 17], [18, 49], [50, 468], [468, 1066], [1067, 1079], [1079, 1683], [1684, 1713], [1713, 2054], [2054, 2113], [2113, 2149], [2149, 2200], [2200, 2238], [2238, 2251], [2251, 2274], [2274, 3093], [3094, 3110], [3110, 3139], [3139, 3259], [3259, 3346], [3346, 3754], [3754, 3967], [3967, 4129], [4129, 4386], ... | nda-20 | Receiving Party may retain some Confidential Information even after the return or destruction of Confidential Information. | Permissible post-agreement possession | Entailment | [47] |
621 | 1609351_0001193125-19-066373_d642137dex99d2.htm | Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeutics, Inc., a Delaware corporation, having an address at 3737 Market Street, Suite 1300... | sec-html | https://www.sec.gov/Archives/edgar/data/0001609351/000119312519066373/d642137dex99d2.htm | [[0, 11], [11, 17], [18, 49], [50, 468], [468, 1066], [1067, 1079], [1079, 1683], [1684, 1713], [1713, 2054], [2054, 2113], [2113, 2149], [2149, 2200], [2200, 2238], [2238, 2251], [2251, 2274], [2274, 3093], [3094, 3110], [3110, 3139], [3139, 3259], [3259, 3346], [3346, 3754], [3754, 3967], [3967, 4129], [4129, 4386], ... | nda-3 | Confidential Information may include verbally conveyed information. | Inclusion of verbally conveyed information | Entailment | [8] |
621 | 1609351_0001193125-19-066373_d642137dex99d2.htm | Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeutics, Inc., a Delaware corporation, having an address at 3737 Market Street, Suite 1300... | sec-html | https://www.sec.gov/Archives/edgar/data/0001609351/000119312519066373/d642137dex99d2.htm | [[0, 11], [11, 17], [18, 49], [50, 468], [468, 1066], [1067, 1079], [1079, 1683], [1684, 1713], [1713, 2054], [2054, 2113], [2113, 2149], [2149, 2200], [2200, 2238], [2238, 2251], [2251, 2274], [2274, 3093], [3094, 3110], [3110, 3139], [3139, 3259], [3259, 3346], [3346, 3754], [3754, 3967], [3967, 4129], [4129, 4386], ... | nda-18 | Receiving Party shall not solicit some of Disclosing Party's representatives. | No solicitation | NotMentioned | [] |
621 | 1609351_0001193125-19-066373_d642137dex99d2.htm | Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeutics, Inc., a Delaware corporation, having an address at 3737 Market Street, Suite 1300... | sec-html | https://www.sec.gov/Archives/edgar/data/0001609351/000119312519066373/d642137dex99d2.htm | [[0, 11], [11, 17], [18, 49], [50, 468], [468, 1066], [1067, 1079], [1079, 1683], [1684, 1713], [1713, 2054], [2054, 2113], [2113, 2149], [2149, 2200], [2200, 2238], [2238, 2251], [2251, 2274], [2274, 3093], [3094, 3110], [3110, 3139], [3139, 3259], [3259, 3346], [3346, 3754], [3754, 3967], [3967, 4129], [4129, 4386], ... | nda-7 | Receiving Party may share some Confidential Information with some third-parties (including consultants, agents and professional advisors). | Sharing with third-parties | Entailment | [17, 20] |
621 | 1609351_0001193125-19-066373_d642137dex99d2.htm | Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeutics, Inc., a Delaware corporation, having an address at 3737 Market Street, Suite 1300... | sec-html | https://www.sec.gov/Archives/edgar/data/0001609351/000119312519066373/d642137dex99d2.htm | [[0, 11], [11, 17], [18, 49], [50, 468], [468, 1066], [1067, 1079], [1079, 1683], [1684, 1713], [1713, 2054], [2054, 2113], [2113, 2149], [2149, 2200], [2200, 2238], [2238, 2251], [2251, 2274], [2274, 3093], [3094, 3110], [3110, 3139], [3139, 3259], [3259, 3346], [3346, 3754], [3754, 3967], [3967, 4129], [4129, 4386], ... | nda-17 | Receiving Party may create a copy of some Confidential Information in some circumstances. | Permissible copy | Entailment | [23, 44] |
621 | 1609351_0001193125-19-066373_d642137dex99d2.htm | Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeutics, Inc., a Delaware corporation, having an address at 3737 Market Street, Suite 1300... | sec-html | https://www.sec.gov/Archives/edgar/data/0001609351/000119312519066373/d642137dex99d2.htm | [[0, 11], [11, 17], [18, 49], [50, 468], [468, 1066], [1067, 1079], [1079, 1683], [1684, 1713], [1713, 2054], [2054, 2113], [2113, 2149], [2149, 2200], [2200, 2238], [2238, 2251], [2251, 2274], [2274, 3093], [3094, 3110], [3110, 3139], [3139, 3259], [3259, 3346], [3346, 3754], [3754, 3967], [3967, 4129], [4129, 4386], ... | nda-8 | Receiving Party shall notify Disclosing Party in case Receiving Party is required by law, regulation or judicial process to disclose any Confidential Information. | Notice on compelled disclosure | Entailment | [36, 37] |
621 | 1609351_0001193125-19-066373_d642137dex99d2.htm | Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeutics, Inc., a Delaware corporation, having an address at 3737 Market Street, Suite 1300... | sec-html | https://www.sec.gov/Archives/edgar/data/0001609351/000119312519066373/d642137dex99d2.htm | [[0, 11], [11, 17], [18, 49], [50, 468], [468, 1066], [1067, 1079], [1079, 1683], [1684, 1713], [1713, 2054], [2054, 2113], [2113, 2149], [2149, 2200], [2200, 2238], [2238, 2251], [2251, 2274], [2274, 3093], [3094, 3110], [3110, 3139], [3139, 3259], [3259, 3346], [3346, 3754], [3754, 3967], [3967, 4129], [4129, 4386], ... | nda-13 | Receiving Party may acquire information similar to Confidential Information from a third party. | Permissible acquirement of similar information | Entailment | [25, 28] |
621 | 1609351_0001193125-19-066373_d642137dex99d2.htm | Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeutics, Inc., a Delaware corporation, having an address at 3737 Market Street, Suite 1300... | sec-html | https://www.sec.gov/Archives/edgar/data/0001609351/000119312519066373/d642137dex99d2.htm | [[0, 11], [11, 17], [18, 49], [50, 468], [468, 1066], [1067, 1079], [1079, 1683], [1684, 1713], [1713, 2054], [2054, 2113], [2113, 2149], [2149, 2200], [2200, 2238], [2238, 2251], [2251, 2274], [2274, 3093], [3094, 3110], [3110, 3139], [3139, 3259], [3259, 3346], [3346, 3754], [3754, 3967], [3967, 4129], [4129, 4386], ... | nda-5 | Receiving Party may share some Confidential Information with some of Receiving Party's employees. | Sharing with employees | Entailment | [17, 20] |
621 | 1609351_0001193125-19-066373_d642137dex99d2.htm | Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeutics, Inc., a Delaware corporation, having an address at 3737 Market Street, Suite 1300... | sec-html | https://www.sec.gov/Archives/edgar/data/0001609351/000119312519066373/d642137dex99d2.htm | [[0, 11], [11, 17], [18, 49], [50, 468], [468, 1066], [1067, 1079], [1079, 1683], [1684, 1713], [1713, 2054], [2054, 2113], [2113, 2149], [2149, 2200], [2200, 2238], [2238, 2251], [2251, 2274], [2274, 3093], [3094, 3110], [3110, 3139], [3139, 3259], [3259, 3346], [3346, 3754], [3754, 3967], [3967, 4129], [4129, 4386], ... | nda-4 | Receiving Party shall not use any Confidential Information for any purpose other than the purposes stated in Agreement. | Limited use | Entailment | [17, 18, 50] |
622 | 1628908_0001193125-15-169530_d838828dex1016.htm | Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27, 2013 (the “Effective Date”) by and between The Advisory Board Company, a Delaware corporatio... | sec-html | https://www.sec.gov/Archives/edgar/data/0001628908/000119312515169530/d838828dex1016.htm | [[0, 13], [14, 34], [35, 83], [84, 468], [469, 477], [478, 660], [661, 833], [834, 980], [981, 1226], [1227, 1243], [1243, 1274], [1275, 1325], [1325, 1590], [1590, 1982], [1982, 2089], [2089, 2243], [2243, 2273], [2273, 2309], [2309, 2839], [2840, 3011], [3011, 3060], [3060, 3071], [3071, 3159], [3159, 3387], [3388, 3... | nda-11 | Receiving Party shall not reverse engineer any objects which embody Disclosing Party's Confidential Information. | No reverse engineering | NotMentioned | [] |
622 | 1628908_0001193125-15-169530_d838828dex1016.htm | Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27, 2013 (the “Effective Date”) by and between The Advisory Board Company, a Delaware corporatio... | sec-html | https://www.sec.gov/Archives/edgar/data/0001628908/000119312515169530/d838828dex1016.htm | [[0, 13], [14, 34], [35, 83], [84, 468], [469, 477], [478, 660], [661, 833], [834, 980], [981, 1226], [1227, 1243], [1243, 1274], [1275, 1325], [1325, 1590], [1590, 1982], [1982, 2089], [2089, 2243], [2243, 2273], [2273, 2309], [2309, 2839], [2840, 3011], [3011, 3060], [3060, 3071], [3071, 3159], [3159, 3387], [3388, 3... | nda-16 | Receiving Party shall destroy or return some Confidential Information upon the termination of Agreement. | Return of confidential information | NotMentioned | [] |
622 | 1628908_0001193125-15-169530_d838828dex1016.htm | Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27, 2013 (the “Effective Date”) by and between The Advisory Board Company, a Delaware corporatio... | sec-html | https://www.sec.gov/Archives/edgar/data/0001628908/000119312515169530/d838828dex1016.htm | [[0, 13], [14, 34], [35, 83], [84, 468], [469, 477], [478, 660], [661, 833], [834, 980], [981, 1226], [1227, 1243], [1243, 1274], [1275, 1325], [1325, 1590], [1590, 1982], [1982, 2089], [2089, 2243], [2243, 2273], [2273, 2309], [2309, 2839], [2840, 3011], [3011, 3060], [3060, 3071], [3071, 3159], [3159, 3387], [3388, 3... | nda-15 | Agreement shall not grant Receiving Party any right to Confidential Information. | No licensing | NotMentioned | [] |
622 | 1628908_0001193125-15-169530_d838828dex1016.htm | Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27, 2013 (the “Effective Date”) by and between The Advisory Board Company, a Delaware corporatio... | sec-html | https://www.sec.gov/Archives/edgar/data/0001628908/000119312515169530/d838828dex1016.htm | [[0, 13], [14, 34], [35, 83], [84, 468], [469, 477], [478, 660], [661, 833], [834, 980], [981, 1226], [1227, 1243], [1243, 1274], [1275, 1325], [1325, 1590], [1590, 1982], [1982, 2089], [2089, 2243], [2243, 2273], [2273, 2309], [2309, 2839], [2840, 3011], [3011, 3060], [3060, 3071], [3071, 3159], [3159, 3387], [3388, 3... | nda-10 | Receiving Party shall not disclose the fact that Agreement was agreed or negotiated. | Confidentiality of Agreement | Entailment | [332] |
622 | 1628908_0001193125-15-169530_d838828dex1016.htm | Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27, 2013 (the “Effective Date”) by and between The Advisory Board Company, a Delaware corporatio... | sec-html | https://www.sec.gov/Archives/edgar/data/0001628908/000119312515169530/d838828dex1016.htm | [[0, 13], [14, 34], [35, 83], [84, 468], [469, 477], [478, 660], [661, 833], [834, 980], [981, 1226], [1227, 1243], [1243, 1274], [1275, 1325], [1325, 1590], [1590, 1982], [1982, 2089], [2089, 2243], [2243, 2273], [2273, 2309], [2309, 2839], [2840, 3011], [3011, 3060], [3060, 3071], [3071, 3159], [3159, 3387], [3388, 3... | nda-2 | Confidential Information shall only include technical information. | None-inclusion of non-technical information | Contradiction | [27] |
622 | 1628908_0001193125-15-169530_d838828dex1016.htm | Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27, 2013 (the “Effective Date”) by and between The Advisory Board Company, a Delaware corporatio... | sec-html | https://www.sec.gov/Archives/edgar/data/0001628908/000119312515169530/d838828dex1016.htm | [[0, 13], [14, 34], [35, 83], [84, 468], [469, 477], [478, 660], [661, 833], [834, 980], [981, 1226], [1227, 1243], [1243, 1274], [1275, 1325], [1325, 1590], [1590, 1982], [1982, 2089], [2089, 2243], [2243, 2273], [2273, 2309], [2309, 2839], [2840, 3011], [3011, 3060], [3060, 3071], [3071, 3159], [3159, 3387], [3388, 3... | nda-1 | All Confidential Information shall be expressly identified by the Disclosing Party. | Explicit identification | Contradiction | [27] |
622 | 1628908_0001193125-15-169530_d838828dex1016.htm | Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27, 2013 (the “Effective Date”) by and between The Advisory Board Company, a Delaware corporatio... | sec-html | https://www.sec.gov/Archives/edgar/data/0001628908/000119312515169530/d838828dex1016.htm | [[0, 13], [14, 34], [35, 83], [84, 468], [469, 477], [478, 660], [661, 833], [834, 980], [981, 1226], [1227, 1243], [1243, 1274], [1275, 1325], [1325, 1590], [1590, 1982], [1982, 2089], [2089, 2243], [2243, 2273], [2273, 2309], [2309, 2839], [2840, 3011], [3011, 3060], [3060, 3071], [3071, 3159], [3159, 3387], [3388, 3... | nda-19 | Some obligations of Agreement may survive termination of Agreement. | Survival of obligations | Entailment | [169, 217] |
622 | 1628908_0001193125-15-169530_d838828dex1016.htm | Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27, 2013 (the “Effective Date”) by and between The Advisory Board Company, a Delaware corporatio... | sec-html | https://www.sec.gov/Archives/edgar/data/0001628908/000119312515169530/d838828dex1016.htm | [[0, 13], [14, 34], [35, 83], [84, 468], [469, 477], [478, 660], [661, 833], [834, 980], [981, 1226], [1227, 1243], [1243, 1274], [1275, 1325], [1325, 1590], [1590, 1982], [1982, 2089], [2089, 2243], [2243, 2273], [2273, 2309], [2309, 2839], [2840, 3011], [3011, 3060], [3060, 3071], [3071, 3159], [3159, 3387], [3388, 3... | nda-12 | Receiving Party may independently develop information similar to Confidential Information. | Permissible development of similar information | Entailment | [28, 31] |
622 | 1628908_0001193125-15-169530_d838828dex1016.htm | Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27, 2013 (the “Effective Date”) by and between The Advisory Board Company, a Delaware corporatio... | sec-html | https://www.sec.gov/Archives/edgar/data/0001628908/000119312515169530/d838828dex1016.htm | [[0, 13], [14, 34], [35, 83], [84, 468], [469, 477], [478, 660], [661, 833], [834, 980], [981, 1226], [1227, 1243], [1243, 1274], [1275, 1325], [1325, 1590], [1590, 1982], [1982, 2089], [2089, 2243], [2243, 2273], [2273, 2309], [2309, 2839], [2840, 3011], [3011, 3060], [3060, 3071], [3071, 3159], [3159, 3387], [3388, 3... | nda-20 | Receiving Party may retain some Confidential Information even after the return or destruction of Confidential Information. | Permissible post-agreement possession | NotMentioned | [] |
622 | 1628908_0001193125-15-169530_d838828dex1016.htm | Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27, 2013 (the “Effective Date”) by and between The Advisory Board Company, a Delaware corporatio... | sec-html | https://www.sec.gov/Archives/edgar/data/0001628908/000119312515169530/d838828dex1016.htm | [[0, 13], [14, 34], [35, 83], [84, 468], [469, 477], [478, 660], [661, 833], [834, 980], [981, 1226], [1227, 1243], [1243, 1274], [1275, 1325], [1325, 1590], [1590, 1982], [1982, 2089], [2089, 2243], [2243, 2273], [2273, 2309], [2309, 2839], [2840, 3011], [3011, 3060], [3060, 3071], [3071, 3159], [3159, 3387], [3388, 3... | nda-3 | Confidential Information may include verbally conveyed information. | Inclusion of verbally conveyed information | Entailment | [27] |
622 | 1628908_0001193125-15-169530_d838828dex1016.htm | Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27, 2013 (the “Effective Date”) by and between The Advisory Board Company, a Delaware corporatio... | sec-html | https://www.sec.gov/Archives/edgar/data/0001628908/000119312515169530/d838828dex1016.htm | [[0, 13], [14, 34], [35, 83], [84, 468], [469, 477], [478, 660], [661, 833], [834, 980], [981, 1226], [1227, 1243], [1243, 1274], [1275, 1325], [1325, 1590], [1590, 1982], [1982, 2089], [2089, 2243], [2243, 2273], [2273, 2309], [2309, 2839], [2840, 3011], [3011, 3060], [3060, 3071], [3071, 3159], [3159, 3387], [3388, 3... | nda-18 | Receiving Party shall not solicit some of Disclosing Party's representatives. | No solicitation | Entailment | [151] |
622 | 1628908_0001193125-15-169530_d838828dex1016.htm | Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27, 2013 (the “Effective Date”) by and between The Advisory Board Company, a Delaware corporatio... | sec-html | https://www.sec.gov/Archives/edgar/data/0001628908/000119312515169530/d838828dex1016.htm | [[0, 13], [14, 34], [35, 83], [84, 468], [469, 477], [478, 660], [661, 833], [834, 980], [981, 1226], [1227, 1243], [1243, 1274], [1275, 1325], [1325, 1590], [1590, 1982], [1982, 2089], [2089, 2243], [2243, 2273], [2273, 2309], [2309, 2839], [2840, 3011], [3011, 3060], [3060, 3071], [3071, 3159], [3159, 3387], [3388, 3... | nda-7 | Receiving Party may share some Confidential Information with some third-parties (including consultants, agents and professional advisors). | Sharing with third-parties | Entailment | [162] |
622 | 1628908_0001193125-15-169530_d838828dex1016.htm | Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27, 2013 (the “Effective Date”) by and between The Advisory Board Company, a Delaware corporatio... | sec-html | https://www.sec.gov/Archives/edgar/data/0001628908/000119312515169530/d838828dex1016.htm | [[0, 13], [14, 34], [35, 83], [84, 468], [469, 477], [478, 660], [661, 833], [834, 980], [981, 1226], [1227, 1243], [1243, 1274], [1275, 1325], [1325, 1590], [1590, 1982], [1982, 2089], [2089, 2243], [2243, 2273], [2273, 2309], [2309, 2839], [2840, 3011], [3011, 3060], [3060, 3071], [3071, 3159], [3159, 3387], [3388, 3... | nda-17 | Receiving Party may create a copy of some Confidential Information in some circumstances. | Permissible copy | Entailment | [163, 166] |
622 | 1628908_0001193125-15-169530_d838828dex1016.htm | Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27, 2013 (the “Effective Date”) by and between The Advisory Board Company, a Delaware corporatio... | sec-html | https://www.sec.gov/Archives/edgar/data/0001628908/000119312515169530/d838828dex1016.htm | [[0, 13], [14, 34], [35, 83], [84, 468], [469, 477], [478, 660], [661, 833], [834, 980], [981, 1226], [1227, 1243], [1243, 1274], [1275, 1325], [1325, 1590], [1590, 1982], [1982, 2089], [2089, 2243], [2243, 2273], [2273, 2309], [2309, 2839], [2840, 3011], [3011, 3060], [3060, 3071], [3071, 3159], [3159, 3387], [3388, 3... | nda-8 | Receiving Party shall notify Disclosing Party in case Receiving Party is required by law, regulation or judicial process to disclose any Confidential Information. | Notice on compelled disclosure | Entailment | [28, 32, 168] |
622 | 1628908_0001193125-15-169530_d838828dex1016.htm | Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27, 2013 (the “Effective Date”) by and between The Advisory Board Company, a Delaware corporatio... | sec-html | https://www.sec.gov/Archives/edgar/data/0001628908/000119312515169530/d838828dex1016.htm | [[0, 13], [14, 34], [35, 83], [84, 468], [469, 477], [478, 660], [661, 833], [834, 980], [981, 1226], [1227, 1243], [1243, 1274], [1275, 1325], [1325, 1590], [1590, 1982], [1982, 2089], [2089, 2243], [2243, 2273], [2273, 2309], [2309, 2839], [2840, 3011], [3011, 3060], [3060, 3071], [3071, 3159], [3159, 3387], [3388, 3... | nda-13 | Receiving Party may acquire information similar to Confidential Information from a third party. | Permissible acquirement of similar information | Entailment | [28, 30, 174, 175] |
622 | 1628908_0001193125-15-169530_d838828dex1016.htm | Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27, 2013 (the “Effective Date”) by and between The Advisory Board Company, a Delaware corporatio... | sec-html | https://www.sec.gov/Archives/edgar/data/0001628908/000119312515169530/d838828dex1016.htm | [[0, 13], [14, 34], [35, 83], [84, 468], [469, 477], [478, 660], [661, 833], [834, 980], [981, 1226], [1227, 1243], [1243, 1274], [1275, 1325], [1325, 1590], [1590, 1982], [1982, 2089], [2089, 2243], [2243, 2273], [2273, 2309], [2309, 2839], [2840, 3011], [3011, 3060], [3060, 3071], [3071, 3159], [3159, 3387], [3388, 3... | nda-5 | Receiving Party may share some Confidential Information with some of Receiving Party's employees. | Sharing with employees | Entailment | [162] |
622 | 1628908_0001193125-15-169530_d838828dex1016.htm | Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27, 2013 (the “Effective Date”) by and between The Advisory Board Company, a Delaware corporatio... | sec-html | https://www.sec.gov/Archives/edgar/data/0001628908/000119312515169530/d838828dex1016.htm | [[0, 13], [14, 34], [35, 83], [84, 468], [469, 477], [478, 660], [661, 833], [834, 980], [981, 1226], [1227, 1243], [1243, 1274], [1275, 1325], [1325, 1590], [1590, 1982], [1982, 2089], [2089, 2243], [2243, 2273], [2273, 2309], [2309, 2839], [2840, 3011], [3011, 3060], [3060, 3071], [3071, 3159], [3159, 3387], [3388, 3... | nda-4 | Receiving Party shall not use any Confidential Information for any purpose other than the purposes stated in Agreement. | Limited use | Entailment | [163, 166] |
623 | 1689602_0001144204-16-140940_v455386_ex10-3.htm | Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua Entities”), Chesapeake Merger Corp., a Delaware corporation and a wholly-owned subsidiary of Par... | sec-html | https://www.sec.gov/Archives/edgar/data/0001689602/000114420416140940/v455386_ex10-3.htm | [[0, 12], [13, 38], [39, 549], [550, 785], [786, 1148], [1149, 1357], [1358, 1377], [1377, 1562], [1563, 1579], [1579, 1678], [1678, 1819], [1820, 3426], [3426, 3549], [3549, 3621], [3621, 3744], [3744, 4033], [4033, 4253], [4254, 4358], [4359, 4495], [4496, 4515], [4516, 4642], [4642, 4958], [4959, 5294], [5294, 5518]... | nda-11 | Receiving Party shall not reverse engineer any objects which embody Disclosing Party's Confidential Information. | No reverse engineering | NotMentioned | [] |
623 | 1689602_0001144204-16-140940_v455386_ex10-3.htm | Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua Entities”), Chesapeake Merger Corp., a Delaware corporation and a wholly-owned subsidiary of Par... | sec-html | https://www.sec.gov/Archives/edgar/data/0001689602/000114420416140940/v455386_ex10-3.htm | [[0, 12], [13, 38], [39, 549], [550, 785], [786, 1148], [1149, 1357], [1358, 1377], [1377, 1562], [1563, 1579], [1579, 1678], [1678, 1819], [1820, 3426], [3426, 3549], [3549, 3621], [3621, 3744], [3744, 4033], [4033, 4253], [4254, 4358], [4359, 4495], [4496, 4515], [4516, 4642], [4642, 4958], [4959, 5294], [5294, 5518]... | nda-16 | Receiving Party shall destroy or return some Confidential Information upon the termination of Agreement. | Return of confidential information | NotMentioned | [] |
623 | 1689602_0001144204-16-140940_v455386_ex10-3.htm | Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua Entities”), Chesapeake Merger Corp., a Delaware corporation and a wholly-owned subsidiary of Par... | sec-html | https://www.sec.gov/Archives/edgar/data/0001689602/000114420416140940/v455386_ex10-3.htm | [[0, 12], [13, 38], [39, 549], [550, 785], [786, 1148], [1149, 1357], [1358, 1377], [1377, 1562], [1563, 1579], [1579, 1678], [1678, 1819], [1820, 3426], [3426, 3549], [3549, 3621], [3621, 3744], [3744, 4033], [4033, 4253], [4254, 4358], [4359, 4495], [4496, 4515], [4516, 4642], [4642, 4958], [4959, 5294], [5294, 5518]... | nda-15 | Agreement shall not grant Receiving Party any right to Confidential Information. | No licensing | Entailment | [34] |
623 | 1689602_0001144204-16-140940_v455386_ex10-3.htm | Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua Entities”), Chesapeake Merger Corp., a Delaware corporation and a wholly-owned subsidiary of Par... | sec-html | https://www.sec.gov/Archives/edgar/data/0001689602/000114420416140940/v455386_ex10-3.htm | [[0, 12], [13, 38], [39, 549], [550, 785], [786, 1148], [1149, 1357], [1358, 1377], [1377, 1562], [1563, 1579], [1579, 1678], [1678, 1819], [1820, 3426], [3426, 3549], [3549, 3621], [3621, 3744], [3744, 4033], [4033, 4253], [4254, 4358], [4359, 4495], [4496, 4515], [4516, 4642], [4642, 4958], [4959, 5294], [5294, 5518]... | nda-10 | Receiving Party shall not disclose the fact that Agreement was agreed or negotiated. | Confidentiality of Agreement | NotMentioned | [] |
623 | 1689602_0001144204-16-140940_v455386_ex10-3.htm | Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua Entities”), Chesapeake Merger Corp., a Delaware corporation and a wholly-owned subsidiary of Par... | sec-html | https://www.sec.gov/Archives/edgar/data/0001689602/000114420416140940/v455386_ex10-3.htm | [[0, 12], [13, 38], [39, 549], [550, 785], [786, 1148], [1149, 1357], [1358, 1377], [1377, 1562], [1563, 1579], [1579, 1678], [1678, 1819], [1820, 3426], [3426, 3549], [3549, 3621], [3621, 3744], [3744, 4033], [4033, 4253], [4254, 4358], [4359, 4495], [4496, 4515], [4516, 4642], [4642, 4958], [4959, 5294], [5294, 5518]... | nda-2 | Confidential Information shall only include technical information. | None-inclusion of non-technical information | Contradiction | [11] |
623 | 1689602_0001144204-16-140940_v455386_ex10-3.htm | Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua Entities”), Chesapeake Merger Corp., a Delaware corporation and a wholly-owned subsidiary of Par... | sec-html | https://www.sec.gov/Archives/edgar/data/0001689602/000114420416140940/v455386_ex10-3.htm | [[0, 12], [13, 38], [39, 549], [550, 785], [786, 1148], [1149, 1357], [1358, 1377], [1377, 1562], [1563, 1579], [1579, 1678], [1678, 1819], [1820, 3426], [3426, 3549], [3549, 3621], [3621, 3744], [3744, 4033], [4033, 4253], [4254, 4358], [4359, 4495], [4496, 4515], [4516, 4642], [4642, 4958], [4959, 5294], [5294, 5518]... | nda-1 | All Confidential Information shall be expressly identified by the Disclosing Party. | Explicit identification | NotMentioned | [] |
623 | 1689602_0001144204-16-140940_v455386_ex10-3.htm | Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua Entities”), Chesapeake Merger Corp., a Delaware corporation and a wholly-owned subsidiary of Par... | sec-html | https://www.sec.gov/Archives/edgar/data/0001689602/000114420416140940/v455386_ex10-3.htm | [[0, 12], [13, 38], [39, 549], [550, 785], [786, 1148], [1149, 1357], [1358, 1377], [1377, 1562], [1563, 1579], [1579, 1678], [1678, 1819], [1820, 3426], [3426, 3549], [3549, 3621], [3621, 3744], [3744, 4033], [4033, 4253], [4254, 4358], [4359, 4495], [4496, 4515], [4516, 4642], [4642, 4958], [4959, 5294], [5294, 5518]... | nda-19 | Some obligations of Agreement may survive termination of Agreement. | Survival of obligations | NotMentioned | [] |
623 | 1689602_0001144204-16-140940_v455386_ex10-3.htm | Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua Entities”), Chesapeake Merger Corp., a Delaware corporation and a wholly-owned subsidiary of Par... | sec-html | https://www.sec.gov/Archives/edgar/data/0001689602/000114420416140940/v455386_ex10-3.htm | [[0, 12], [13, 38], [39, 549], [550, 785], [786, 1148], [1149, 1357], [1358, 1377], [1377, 1562], [1563, 1579], [1579, 1678], [1678, 1819], [1820, 3426], [3426, 3549], [3549, 3621], [3621, 3744], [3744, 4033], [4033, 4253], [4254, 4358], [4359, 4495], [4496, 4515], [4516, 4642], [4642, 4958], [4959, 5294], [5294, 5518]... | nda-12 | Receiving Party may independently develop information similar to Confidential Information. | Permissible development of similar information | Entailment | [12, 16] |
623 | 1689602_0001144204-16-140940_v455386_ex10-3.htm | Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua Entities”), Chesapeake Merger Corp., a Delaware corporation and a wholly-owned subsidiary of Par... | sec-html | https://www.sec.gov/Archives/edgar/data/0001689602/000114420416140940/v455386_ex10-3.htm | [[0, 12], [13, 38], [39, 549], [550, 785], [786, 1148], [1149, 1357], [1358, 1377], [1377, 1562], [1563, 1579], [1579, 1678], [1678, 1819], [1820, 3426], [3426, 3549], [3549, 3621], [3621, 3744], [3744, 4033], [4033, 4253], [4254, 4358], [4359, 4495], [4496, 4515], [4516, 4642], [4642, 4958], [4959, 5294], [5294, 5518]... | nda-20 | Receiving Party may retain some Confidential Information even after the return or destruction of Confidential Information. | Permissible post-agreement possession | NotMentioned | [] |
623 | 1689602_0001144204-16-140940_v455386_ex10-3.htm | Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua Entities”), Chesapeake Merger Corp., a Delaware corporation and a wholly-owned subsidiary of Par... | sec-html | https://www.sec.gov/Archives/edgar/data/0001689602/000114420416140940/v455386_ex10-3.htm | [[0, 12], [13, 38], [39, 549], [550, 785], [786, 1148], [1149, 1357], [1358, 1377], [1377, 1562], [1563, 1579], [1579, 1678], [1678, 1819], [1820, 3426], [3426, 3549], [3549, 3621], [3621, 3744], [3744, 4033], [4033, 4253], [4254, 4358], [4359, 4495], [4496, 4515], [4516, 4642], [4642, 4958], [4959, 5294], [5294, 5518]... | nda-3 | Confidential Information may include verbally conveyed information. | Inclusion of verbally conveyed information | Entailment | [11] |
623 | 1689602_0001144204-16-140940_v455386_ex10-3.htm | Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua Entities”), Chesapeake Merger Corp., a Delaware corporation and a wholly-owned subsidiary of Par... | sec-html | https://www.sec.gov/Archives/edgar/data/0001689602/000114420416140940/v455386_ex10-3.htm | [[0, 12], [13, 38], [39, 549], [550, 785], [786, 1148], [1149, 1357], [1358, 1377], [1377, 1562], [1563, 1579], [1579, 1678], [1678, 1819], [1820, 3426], [3426, 3549], [3549, 3621], [3621, 3744], [3744, 4033], [4033, 4253], [4254, 4358], [4359, 4495], [4496, 4515], [4516, 4642], [4642, 4958], [4959, 5294], [5294, 5518]... | nda-18 | Receiving Party shall not solicit some of Disclosing Party's representatives. | No solicitation | Entailment | [43] |
623 | 1689602_0001144204-16-140940_v455386_ex10-3.htm | Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua Entities”), Chesapeake Merger Corp., a Delaware corporation and a wholly-owned subsidiary of Par... | sec-html | https://www.sec.gov/Archives/edgar/data/0001689602/000114420416140940/v455386_ex10-3.htm | [[0, 12], [13, 38], [39, 549], [550, 785], [786, 1148], [1149, 1357], [1358, 1377], [1377, 1562], [1563, 1579], [1579, 1678], [1678, 1819], [1820, 3426], [3426, 3549], [3549, 3621], [3621, 3744], [3744, 4033], [4033, 4253], [4254, 4358], [4359, 4495], [4496, 4515], [4516, 4642], [4642, 4958], [4959, 5294], [5294, 5518]... | nda-7 | Receiving Party may share some Confidential Information with some third-parties (including consultants, agents and professional advisors). | Sharing with third-parties | Contradiction | [38] |
623 | 1689602_0001144204-16-140940_v455386_ex10-3.htm | Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua Entities”), Chesapeake Merger Corp., a Delaware corporation and a wholly-owned subsidiary of Par... | sec-html | https://www.sec.gov/Archives/edgar/data/0001689602/000114420416140940/v455386_ex10-3.htm | [[0, 12], [13, 38], [39, 549], [550, 785], [786, 1148], [1149, 1357], [1358, 1377], [1377, 1562], [1563, 1579], [1579, 1678], [1678, 1819], [1820, 3426], [3426, 3549], [3549, 3621], [3621, 3744], [3744, 4033], [4033, 4253], [4254, 4358], [4359, 4495], [4496, 4515], [4516, 4642], [4642, 4958], [4959, 5294], [5294, 5518]... | nda-17 | Receiving Party may create a copy of some Confidential Information in some circumstances. | Permissible copy | NotMentioned | [] |
623 | 1689602_0001144204-16-140940_v455386_ex10-3.htm | Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua Entities”), Chesapeake Merger Corp., a Delaware corporation and a wholly-owned subsidiary of Par... | sec-html | https://www.sec.gov/Archives/edgar/data/0001689602/000114420416140940/v455386_ex10-3.htm | [[0, 12], [13, 38], [39, 549], [550, 785], [786, 1148], [1149, 1357], [1358, 1377], [1377, 1562], [1563, 1579], [1579, 1678], [1678, 1819], [1820, 3426], [3426, 3549], [3549, 3621], [3621, 3744], [3744, 4033], [4033, 4253], [4254, 4358], [4359, 4495], [4496, 4515], [4516, 4642], [4642, 4958], [4959, 5294], [5294, 5518]... | nda-8 | Receiving Party shall notify Disclosing Party in case Receiving Party is required by law, regulation or judicial process to disclose any Confidential Information. | Notice on compelled disclosure | Entailment | [39] |
623 | 1689602_0001144204-16-140940_v455386_ex10-3.htm | Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua Entities”), Chesapeake Merger Corp., a Delaware corporation and a wholly-owned subsidiary of Par... | sec-html | https://www.sec.gov/Archives/edgar/data/0001689602/000114420416140940/v455386_ex10-3.htm | [[0, 12], [13, 38], [39, 549], [550, 785], [786, 1148], [1149, 1357], [1358, 1377], [1377, 1562], [1563, 1579], [1579, 1678], [1678, 1819], [1820, 3426], [3426, 3549], [3549, 3621], [3621, 3744], [3744, 4033], [4033, 4253], [4254, 4358], [4359, 4495], [4496, 4515], [4516, 4642], [4642, 4958], [4959, 5294], [5294, 5518]... | nda-13 | Receiving Party may acquire information similar to Confidential Information from a third party. | Permissible acquirement of similar information | Entailment | [12, 16] |
623 | 1689602_0001144204-16-140940_v455386_ex10-3.htm | Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua Entities”), Chesapeake Merger Corp., a Delaware corporation and a wholly-owned subsidiary of Par... | sec-html | https://www.sec.gov/Archives/edgar/data/0001689602/000114420416140940/v455386_ex10-3.htm | [[0, 12], [13, 38], [39, 549], [550, 785], [786, 1148], [1149, 1357], [1358, 1377], [1377, 1562], [1563, 1579], [1579, 1678], [1678, 1819], [1820, 3426], [3426, 3549], [3549, 3621], [3621, 3744], [3744, 4033], [4033, 4253], [4254, 4358], [4359, 4495], [4496, 4515], [4516, 4642], [4642, 4958], [4959, 5294], [5294, 5518]... | nda-5 | Receiving Party may share some Confidential Information with some of Receiving Party's employees. | Sharing with employees | Contradiction | [38] |
623 | 1689602_0001144204-16-140940_v455386_ex10-3.htm | Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua Entities”), Chesapeake Merger Corp., a Delaware corporation and a wholly-owned subsidiary of Par... | sec-html | https://www.sec.gov/Archives/edgar/data/0001689602/000114420416140940/v455386_ex10-3.htm | [[0, 12], [13, 38], [39, 549], [550, 785], [786, 1148], [1149, 1357], [1358, 1377], [1377, 1562], [1563, 1579], [1579, 1678], [1678, 1819], [1820, 3426], [3426, 3549], [3549, 3621], [3621, 3744], [3744, 4033], [4033, 4253], [4254, 4358], [4359, 4495], [4496, 4515], [4516, 4642], [4642, 4958], [4959, 5294], [5294, 5518]... | nda-4 | Receiving Party shall not use any Confidential Information for any purpose other than the purposes stated in Agreement. | Limited use | Entailment | [36, 38] |
624 | 1693664_0001193125-18-171470_d426098dex99d3.htm | Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an Indiana corporation (“Buyer” and with Seller referred to collectively as the “Parties” and indiv... | sec-html | https://www.sec.gov/Archives/edgar/data/0001693664/000119312518171470/d426098dex99d3.htm | [[0, 8], [8, 14], [15, 39], [40, 342], [343, 677], [677, 905], [905, 1047], [1048, 1125], [1126, 1192], [1192, 1332], [1333, 1542], [1543, 1684], [1685, 1930], [1930, 2137], [2138, 2166], [2166, 2411], [2411, 2664], [2665, 2700], [2700, 3018], [3019, 3656], [3656, 3880], [3881, 3906], [3907, 3972], [3973, 4142], [4143,... | nda-11 | Receiving Party shall not reverse engineer any objects which embody Disclosing Party's Confidential Information. | No reverse engineering | NotMentioned | [] |
624 | 1693664_0001193125-18-171470_d426098dex99d3.htm | Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an Indiana corporation (“Buyer” and with Seller referred to collectively as the “Parties” and indiv... | sec-html | https://www.sec.gov/Archives/edgar/data/0001693664/000119312518171470/d426098dex99d3.htm | [[0, 8], [8, 14], [15, 39], [40, 342], [343, 677], [677, 905], [905, 1047], [1048, 1125], [1126, 1192], [1192, 1332], [1333, 1542], [1543, 1684], [1685, 1930], [1930, 2137], [2138, 2166], [2166, 2411], [2411, 2664], [2665, 2700], [2700, 3018], [3019, 3656], [3656, 3880], [3881, 3906], [3907, 3972], [3973, 4142], [4143,... | nda-16 | Receiving Party shall destroy or return some Confidential Information upon the termination of Agreement. | Return of confidential information | NotMentioned | [] |
624 | 1693664_0001193125-18-171470_d426098dex99d3.htm | Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an Indiana corporation (“Buyer” and with Seller referred to collectively as the “Parties” and indiv... | sec-html | https://www.sec.gov/Archives/edgar/data/0001693664/000119312518171470/d426098dex99d3.htm | [[0, 8], [8, 14], [15, 39], [40, 342], [343, 677], [677, 905], [905, 1047], [1048, 1125], [1126, 1192], [1192, 1332], [1333, 1542], [1543, 1684], [1685, 1930], [1930, 2137], [2138, 2166], [2166, 2411], [2411, 2664], [2665, 2700], [2700, 3018], [3019, 3656], [3656, 3880], [3881, 3906], [3907, 3972], [3973, 4142], [4143,... | nda-15 | Agreement shall not grant Receiving Party any right to Confidential Information. | No licensing | Entailment | [109] |
624 | 1693664_0001193125-18-171470_d426098dex99d3.htm | Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an Indiana corporation (“Buyer” and with Seller referred to collectively as the “Parties” and indiv... | sec-html | https://www.sec.gov/Archives/edgar/data/0001693664/000119312518171470/d426098dex99d3.htm | [[0, 8], [8, 14], [15, 39], [40, 342], [343, 677], [677, 905], [905, 1047], [1048, 1125], [1126, 1192], [1192, 1332], [1333, 1542], [1543, 1684], [1685, 1930], [1930, 2137], [2138, 2166], [2166, 2411], [2411, 2664], [2665, 2700], [2700, 3018], [3019, 3656], [3656, 3880], [3881, 3906], [3907, 3972], [3973, 4142], [4143,... | nda-10 | Receiving Party shall not disclose the fact that Agreement was agreed or negotiated. | Confidentiality of Agreement | Entailment | [91, 95, 96, 97] |
624 | 1693664_0001193125-18-171470_d426098dex99d3.htm | Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an Indiana corporation (“Buyer” and with Seller referred to collectively as the “Parties” and indiv... | sec-html | https://www.sec.gov/Archives/edgar/data/0001693664/000119312518171470/d426098dex99d3.htm | [[0, 8], [8, 14], [15, 39], [40, 342], [343, 677], [677, 905], [905, 1047], [1048, 1125], [1126, 1192], [1192, 1332], [1333, 1542], [1543, 1684], [1685, 1930], [1930, 2137], [2138, 2166], [2166, 2411], [2411, 2664], [2665, 2700], [2700, 3018], [3019, 3656], [3656, 3880], [3881, 3906], [3907, 3972], [3973, 4142], [4143,... | nda-2 | Confidential Information shall only include technical information. | None-inclusion of non-technical information | Contradiction | [91, 92] |
624 | 1693664_0001193125-18-171470_d426098dex99d3.htm | Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an Indiana corporation (“Buyer” and with Seller referred to collectively as the “Parties” and indiv... | sec-html | https://www.sec.gov/Archives/edgar/data/0001693664/000119312518171470/d426098dex99d3.htm | [[0, 8], [8, 14], [15, 39], [40, 342], [343, 677], [677, 905], [905, 1047], [1048, 1125], [1126, 1192], [1192, 1332], [1333, 1542], [1543, 1684], [1685, 1930], [1930, 2137], [2138, 2166], [2166, 2411], [2411, 2664], [2665, 2700], [2700, 3018], [3019, 3656], [3656, 3880], [3881, 3906], [3907, 3972], [3973, 4142], [4143,... | nda-1 | All Confidential Information shall be expressly identified by the Disclosing Party. | Explicit identification | NotMentioned | [] |
624 | 1693664_0001193125-18-171470_d426098dex99d3.htm | Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an Indiana corporation (“Buyer” and with Seller referred to collectively as the “Parties” and indiv... | sec-html | https://www.sec.gov/Archives/edgar/data/0001693664/000119312518171470/d426098dex99d3.htm | [[0, 8], [8, 14], [15, 39], [40, 342], [343, 677], [677, 905], [905, 1047], [1048, 1125], [1126, 1192], [1192, 1332], [1333, 1542], [1543, 1684], [1685, 1930], [1930, 2137], [2138, 2166], [2166, 2411], [2411, 2664], [2665, 2700], [2700, 3018], [3019, 3656], [3656, 3880], [3881, 3906], [3907, 3972], [3973, 4142], [4143,... | nda-19 | Some obligations of Agreement may survive termination of Agreement. | Survival of obligations | Entailment | [35, 117] |
624 | 1693664_0001193125-18-171470_d426098dex99d3.htm | Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an Indiana corporation (“Buyer” and with Seller referred to collectively as the “Parties” and indiv... | sec-html | https://www.sec.gov/Archives/edgar/data/0001693664/000119312518171470/d426098dex99d3.htm | [[0, 8], [8, 14], [15, 39], [40, 342], [343, 677], [677, 905], [905, 1047], [1048, 1125], [1126, 1192], [1192, 1332], [1333, 1542], [1543, 1684], [1685, 1930], [1930, 2137], [2138, 2166], [2166, 2411], [2411, 2664], [2665, 2700], [2700, 3018], [3019, 3656], [3656, 3880], [3881, 3906], [3907, 3972], [3973, 4142], [4143,... | nda-12 | Receiving Party may independently develop information similar to Confidential Information. | Permissible development of similar information | Entailment | [98, 102] |
624 | 1693664_0001193125-18-171470_d426098dex99d3.htm | Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an Indiana corporation (“Buyer” and with Seller referred to collectively as the “Parties” and indiv... | sec-html | https://www.sec.gov/Archives/edgar/data/0001693664/000119312518171470/d426098dex99d3.htm | [[0, 8], [8, 14], [15, 39], [40, 342], [343, 677], [677, 905], [905, 1047], [1048, 1125], [1126, 1192], [1192, 1332], [1333, 1542], [1543, 1684], [1685, 1930], [1930, 2137], [2138, 2166], [2166, 2411], [2411, 2664], [2665, 2700], [2700, 3018], [3019, 3656], [3656, 3880], [3881, 3906], [3907, 3972], [3973, 4142], [4143,... | nda-20 | Receiving Party may retain some Confidential Information even after the return or destruction of Confidential Information. | Permissible post-agreement possession | Entailment | [34] |
624 | 1693664_0001193125-18-171470_d426098dex99d3.htm | Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an Indiana corporation (“Buyer” and with Seller referred to collectively as the “Parties” and indiv... | sec-html | https://www.sec.gov/Archives/edgar/data/0001693664/000119312518171470/d426098dex99d3.htm | [[0, 8], [8, 14], [15, 39], [40, 342], [343, 677], [677, 905], [905, 1047], [1048, 1125], [1126, 1192], [1192, 1332], [1333, 1542], [1543, 1684], [1685, 1930], [1930, 2137], [2138, 2166], [2166, 2411], [2411, 2664], [2665, 2700], [2700, 3018], [3019, 3656], [3656, 3880], [3881, 3906], [3907, 3972], [3973, 4142], [4143,... | nda-3 | Confidential Information may include verbally conveyed information. | Inclusion of verbally conveyed information | Entailment | [91, 92] |
624 | 1693664_0001193125-18-171470_d426098dex99d3.htm | Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an Indiana corporation (“Buyer” and with Seller referred to collectively as the “Parties” and indiv... | sec-html | https://www.sec.gov/Archives/edgar/data/0001693664/000119312518171470/d426098dex99d3.htm | [[0, 8], [8, 14], [15, 39], [40, 342], [343, 677], [677, 905], [905, 1047], [1048, 1125], [1126, 1192], [1192, 1332], [1333, 1542], [1543, 1684], [1685, 1930], [1930, 2137], [2138, 2166], [2166, 2411], [2411, 2664], [2665, 2700], [2700, 3018], [3019, 3656], [3656, 3880], [3881, 3906], [3907, 3972], [3973, 4142], [4143,... | nda-18 | Receiving Party shall not solicit some of Disclosing Party's representatives. | No solicitation | Entailment | [16, 37] |
624 | 1693664_0001193125-18-171470_d426098dex99d3.htm | Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an Indiana corporation (“Buyer” and with Seller referred to collectively as the “Parties” and indiv... | sec-html | https://www.sec.gov/Archives/edgar/data/0001693664/000119312518171470/d426098dex99d3.htm | [[0, 8], [8, 14], [15, 39], [40, 342], [343, 677], [677, 905], [905, 1047], [1048, 1125], [1126, 1192], [1192, 1332], [1333, 1542], [1543, 1684], [1685, 1930], [1930, 2137], [2138, 2166], [2166, 2411], [2411, 2664], [2665, 2700], [2700, 3018], [3019, 3656], [3656, 3880], [3881, 3906], [3907, 3972], [3973, 4142], [4143,... | nda-7 | Receiving Party may share some Confidential Information with some third-parties (including consultants, agents and professional advisors). | Sharing with third-parties | Entailment | [24, 25, 104, 105, 106] |
624 | 1693664_0001193125-18-171470_d426098dex99d3.htm | Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an Indiana corporation (“Buyer” and with Seller referred to collectively as the “Parties” and indiv... | sec-html | https://www.sec.gov/Archives/edgar/data/0001693664/000119312518171470/d426098dex99d3.htm | [[0, 8], [8, 14], [15, 39], [40, 342], [343, 677], [677, 905], [905, 1047], [1048, 1125], [1126, 1192], [1192, 1332], [1333, 1542], [1543, 1684], [1685, 1930], [1930, 2137], [2138, 2166], [2166, 2411], [2411, 2664], [2665, 2700], [2700, 3018], [3019, 3656], [3656, 3880], [3881, 3906], [3907, 3972], [3973, 4142], [4143,... | nda-17 | Receiving Party may create a copy of some Confidential Information in some circumstances. | Permissible copy | NotMentioned | [] |
624 | 1693664_0001193125-18-171470_d426098dex99d3.htm | Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an Indiana corporation (“Buyer” and with Seller referred to collectively as the “Parties” and indiv... | sec-html | https://www.sec.gov/Archives/edgar/data/0001693664/000119312518171470/d426098dex99d3.htm | [[0, 8], [8, 14], [15, 39], [40, 342], [343, 677], [677, 905], [905, 1047], [1048, 1125], [1126, 1192], [1192, 1332], [1333, 1542], [1543, 1684], [1685, 1930], [1930, 2137], [2138, 2166], [2166, 2411], [2411, 2664], [2665, 2700], [2700, 3018], [3019, 3656], [3656, 3880], [3881, 3906], [3907, 3972], [3973, 4142], [4143,... | nda-8 | Receiving Party shall notify Disclosing Party in case Receiving Party is required by law, regulation or judicial process to disclose any Confidential Information. | Notice on compelled disclosure | Entailment | [30] |
624 | 1693664_0001193125-18-171470_d426098dex99d3.htm | Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an Indiana corporation (“Buyer” and with Seller referred to collectively as the “Parties” and indiv... | sec-html | https://www.sec.gov/Archives/edgar/data/0001693664/000119312518171470/d426098dex99d3.htm | [[0, 8], [8, 14], [15, 39], [40, 342], [343, 677], [677, 905], [905, 1047], [1048, 1125], [1126, 1192], [1192, 1332], [1333, 1542], [1543, 1684], [1685, 1930], [1930, 2137], [2138, 2166], [2166, 2411], [2411, 2664], [2665, 2700], [2700, 3018], [3019, 3656], [3656, 3880], [3881, 3906], [3907, 3972], [3973, 4142], [4143,... | nda-13 | Receiving Party may acquire information similar to Confidential Information from a third party. | Permissible acquirement of similar information | Entailment | [98, 101] |
624 | 1693664_0001193125-18-171470_d426098dex99d3.htm | Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an Indiana corporation (“Buyer” and with Seller referred to collectively as the “Parties” and indiv... | sec-html | https://www.sec.gov/Archives/edgar/data/0001693664/000119312518171470/d426098dex99d3.htm | [[0, 8], [8, 14], [15, 39], [40, 342], [343, 677], [677, 905], [905, 1047], [1048, 1125], [1126, 1192], [1192, 1332], [1333, 1542], [1543, 1684], [1685, 1930], [1930, 2137], [2138, 2166], [2166, 2411], [2411, 2664], [2665, 2700], [2700, 3018], [3019, 3656], [3656, 3880], [3881, 3906], [3907, 3972], [3973, 4142], [4143,... | nda-5 | Receiving Party may share some Confidential Information with some of Receiving Party's employees. | Sharing with employees | Entailment | [24, 25, 104, 105, 106] |
624 | 1693664_0001193125-18-171470_d426098dex99d3.htm | Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an Indiana corporation (“Buyer” and with Seller referred to collectively as the “Parties” and indiv... | sec-html | https://www.sec.gov/Archives/edgar/data/0001693664/000119312518171470/d426098dex99d3.htm | [[0, 8], [8, 14], [15, 39], [40, 342], [343, 677], [677, 905], [905, 1047], [1048, 1125], [1126, 1192], [1192, 1332], [1333, 1542], [1543, 1684], [1685, 1930], [1930, 2137], [2138, 2166], [2166, 2411], [2411, 2664], [2665, 2700], [2700, 3018], [3019, 3656], [3656, 3880], [3881, 3906], [3907, 3972], [3973, 4142], [4143,... | nda-4 | Receiving Party shall not use any Confidential Information for any purpose other than the purposes stated in Agreement. | Limited use | Entailment | [9, 10, 16] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.